199 related articles for article (PubMed ID: 35078814)
1. Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.
Devin J; Cañeque T; Lin YL; Mondoulet L; Veyrune JL; Abouladze M; Garcia De Paco E; Karmous Gadacha O; Cartron G; Pasero P; Bret C; Rodriguez R; Moreaux J
Cancer Res; 2022 Mar; 82(6):998-1012. PubMed ID: 35078814
[TBL] [Abstract][Full Text] [Related]
2. TAK1 is a druggable kinase for diffuse large B-cell lymphoma.
Wu Y; Yang R; Ming Y; Xu Y; Chen H; Yao M; Chen X; Mao R; Fan Y
Cell Biochem Funct; 2019 Apr; 37(3):153-160. PubMed ID: 30907011
[TBL] [Abstract][Full Text] [Related]
3. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
[TBL] [Abstract][Full Text] [Related]
4. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
[TBL] [Abstract][Full Text] [Related]
5. microRNA‑196a‑3p inhibits cell proliferation and promotes cell apoptosis by targeting ADP ribosylation factor 4 in diffuse large B‑cell lymphoma.
Fu J; Lou X; Wan S; Zhao X; Chen Z; Zhu M; Guo L; Wu D; Wang S
Oncol Rep; 2021 Feb; 45(2):764-775. PubMed ID: 33416178
[TBL] [Abstract][Full Text] [Related]
6. Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma.
Weng J; Chen L; Liu H; Yang XP; Huang L
Inflammation; 2022 Jun; 45(3):1146-1161. PubMed ID: 35064379
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.
Trabucco SE; Gerstein RM; Evens AM; Bradner JE; Shultz LD; Greiner DL; Zhang H
Clin Cancer Res; 2015 Jan; 21(1):113-22. PubMed ID: 25009295
[TBL] [Abstract][Full Text] [Related]
8. MiR-645 regulates the proliferation and apoptosis of diffuse large B-cell lymphoma by targeting DACH1.
Wang R; Shen J; Su N; Wang Q; Zhang M; Liu C
Hum Cell; 2020 Oct; 33(4):1091-1098. PubMed ID: 32529465
[TBL] [Abstract][Full Text] [Related]
9. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
[TBL] [Abstract][Full Text] [Related]
10. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
[TBL] [Abstract][Full Text] [Related]
12. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.
Singh RR; Kunkalla K; Qu C; Schlette E; Neelapu SS; Samaniego F; Vega F
Oncogene; 2011 Dec; 30(49):4874-86. PubMed ID: 21625222
[TBL] [Abstract][Full Text] [Related]
13. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
[TBL] [Abstract][Full Text] [Related]
14. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells.
Best S; Hashiguchi T; Kittai A; Bruss N; Paiva C; Okada C; Liu T; Berger A; Danilov AV
Blood Adv; 2019 Jan; 3(1):51-62. PubMed ID: 30617217
[TBL] [Abstract][Full Text] [Related]
15. Computational modeling of DLBCL predicts response to BH3-mimetics.
Cloete I; Smith VM; Jackson RA; Pepper A; Pepper C; Vogler M; Dyer MJS; Mitchell S
NPJ Syst Biol Appl; 2023 Jun; 9(1):23. PubMed ID: 37280330
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of ENKD1 disrupts cellular homeostasis to promote lymphoma development.
Song T; He N; Hao Z; Yang Y
J Cell Physiol; 2023 Jun; 238(6):1308-1323. PubMed ID: 36960713
[TBL] [Abstract][Full Text] [Related]
17. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
Wang S; Sun L
Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.
Li C; Thompson MA; Tamayo AT; Zuo Z; Lee J; Vega F; Ford RJ; Pham LV
Oncotarget; 2012 Mar; 3(3):314-26. PubMed ID: 22447839
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
